Ilya Gipp, MD, PhD, presented “Connected Care and Latest Developments in Prostate Cancer Management. Sponsored by Philips” during the 6th Global Summit on Precision Diagnosis and Treatment of Prostate Cancer on September 22, 2022.
How to cite: Gipp, Ilya. “Connected Care and Latest Developments in Prostate Cancer Management. Sponsored by Philips” September 22, 2022. Accessed May 2024. https://grandroundsinurology.com/connected-care-and-latest-developments-in-prostate-cancer-management-sponsored-by-philips/
Connected Care and Latest Developments in Prostate Cancer Management. Sponsored by Philips – Summary
Ilya Gipp, MD, PhD, Medical Officer for Philips, discusses connected care and how it can support some of the most promising new developments in prostate cancer management. He begins with a discussion of advances in multiparametric magnetic resonance imaging (mpMRI) of the prostate and whether and to what extent imaging data is used by physicians. He cites conclusions on the use of 68Ga-PSMA positron emission tomography/computed tomography (PET/CT) as a superior alternative for high-risk prostate cancer patients before explaining the integrated Prostate Imaging Reporting and Data System (PI-RADS) used for exam reports. Dr. Gipp addresses data extraction and analytics with regard to biopsy samples, explaining that new technologies and workflows are enabling more integrated diagnostics. Dr. Gipp points out that this does not solve communication challenges among professionals across disciplines (urologists, radiologists, pathologists), and introduces the idea of connected care. He discusses connecting radiology and urology professionals by sharing actionable data insights and opening new possibilities. Dr. Gipp turns to the role of data scientists and machine learning algorithms in improving MRI-based Gleason scoring, staging, and predicting response to therapy. Dr. Gipp turns to diagnostic prostate cancer risk-stratification and cites a study that progressed from initial in vitro characterizations to clinical validation in patient cohorts with longitudinal and biological outcomes. He emphasizes the importance of connected data and ensuring clinicians and diagnosticians come together and look more broadly at the whole patient picture. Dr. Gipp illustrates an example of prostate cancer patient data orchestration, including simple, graphic representation of data elements such as lab results, 3D modeling based on prostate biopsy, radiology, and pathology. Dr. Gipp explains that connecting prostate cancer care with efficient workflow and actionable insights is important because more therapy options are becoming available, such as focal laser ablation, prostatic artery embolization, high-intensity focused ultrasound (HIFU), irreversible electroporation, focal brachytherapy, radiofrequent ablation, photodynamic therapy, and cryoablation. He emphasizes that connected care and the toolsets becoming available can support all of these. Dr. Gipp cites promising therapies such as MRI-guided transurethral ultrasound ablation (TULSA), seminal vesicle salvage, and dose painting RT. He posits the reason these approaches are not yet being used or data validated is due to a disconnect across the professions. Dr. Gipp concludes with a graphic summary of connected prostate cancer care that is data-driven and patient-centric. He emphasizes that connected care promises efficient, consistent, and high-quality care at every step. This is totally possible today with the proper orchestration of data and efforts to avoid disciplinary silos. Dr. Gipp concludes that connected prostate cancer care opens possibilities for adoptions of new tools, methods, and treatment regimens, opining that “connected prostate cancer care is the future.”
The Global Summit on Precision Diagnosis and Treatment of Prostate Cancer is a unique multi-disciplinary forum organized to inform the key health care stakeholders about the emerging advances in clinical case and research and create a consensus-based vision for the future of precision care and educational and research strategy for its realization. The mission of the Summit is to fill the currently existing gap between the key experts of in vivo imaging, the world authorities in the in vitro fluid- and tissue-based molecular diagnostics, including genomics, and thought leaders in the development of novel observation strategies (e.g., active surveillance, or AS) and therapeutic interventions.
